Skip to main content

Market Overview

HOOKIPA Pharma: Q1 Earnings Insights



Shares of HOOKIPA Pharma (NASDAQ:HOOK) fell 6.1% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share fell 23.26% year over year to ($0.53), which were in line with the estimate of ($0.53).

Revenue of $5,301,000 rose by 43.43% from the same period last year, which beat the estimate of $3,970,000.

Looking Ahead

Earnings guidance hasn't been issued by the company for now.

HOOKIPA Pharma hasn't issued any revenue guidance for the time being.

Recent Stock Performance

Company's 52-week high was at $16.15

52-week low: $8.10

Price action over last quarter: Up 2.72%

Company Overview

HOOKIPA Pharma Inc is a clinical stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. It uses off-the-shelf technologies, VaxWave and TheraT, to elicit directly within patients a response of antigen-specific killer T cells and antibodies.


Related Articles (HOOK)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at